Trial ID or NCT#
The maximum tolerated dose of 3-session (ie, treatment) stereotactic radiosurgery (SRS) to treat brain metastases greater than 4.2 cm³ in size will be determined. This study investigates if increasing radiation dose improves outcome for patients without greater toxicity (side effects).
A Phase I/II Study of Fractionated Stereotactic Radiosurgery to Treat Large Brain Metastases
Contact us to find out if this trial is right for you.